Adrenal insufficiency and the use of mineralocorticoid treatment in male patients with adrenoleukodystrophy; a retrospective analysis of an institutional database
AI is highly prevalent among ALD patients, with approximately 40% of those with a diagnosis of AI undergoing mineralocorticoid replacement therapy. Further research is warranted to delineate the characteristics of patients predisposed to developing mineralocorticoid deficiency within the context of ALD and AI.
Authors
- Michael Salim (ORCID: https://orcid.org/0000-0002-4800-1593)
- Kidmealem Zekarias (ORCID: https://orcid.org/0000-0001-6787-5846)
- Angela Radulescu (ORCID: https://orcid.org/0000-0003-2274-4265)
- Katelyn Tessier (ORCID: https://orcid.org/0000-0002-5513-583X)
Institutions
- University of Minnesota (US)
- University of Minnesota Medical Center (US)
Publication Details
- Journal
- BMC Endocrine Disorders
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1186/s12902-024-01712-3
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Center for Advancing Translational Sciences